Managing Ocular Toxicities in Patients With Cancer: Understanding ADCs and the ECP’s Role in Collaborative Management Therapy on the Horizon (CME Credit)
View More
Managing Ocular Toxicities in Patients With Cancer: Understanding ADCs and the ECP’s Role in Collaborative Management Therapy on the Horizon (COPE Credit)
View More
SimulatED™: Applying Advanced Treatment for nAMD & DME - Simulating New Strategies for Clinical Management
View More
Illuminating the Power of Collaborative Care in nAMD and DME: Advancing the Shift to Treatment Innovations
February 2, 2025
Register Now!
EnVision Summit
February 14-17, 2025
Register Now!
Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments
March 9, 2025
Register Now!
CRU Eye Symposium
March 28-30, 2025
Register Now!
Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (CME Track)
View More
Community Practice Connections™: Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention (CME Track)
View More
Assessing the Evidence for Extending Treatment Intervals in nAMD and DME Management – Expert Insights into Innovative Approaches (CME Track)
View More
Assessing the Evidence for Extending Treatment Intervals in nAMD and DME Management – Expert Insights into Innovative Approaches (COPE Track)
View More
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics (CME Track)
View More
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics (COPE Track)
View More
Community Practice Connections™: Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention (COPE Track)
View More
Surv.AI Says: Real-World Insights Into Patient Burden & Evolving Strategies in nAMD and DME (CME Credit)
View More
Surv.AI Says: Real-World Insights into Patient Burden & Evolving Strategies in nAMD and DME (COPE Credit)
View More
Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (COPE Track)
View More
Reimagining Dry Eye Disease: Delineating the Role of Evaporation From Inflammation and Insights Into Optimizing Treatment (COPE Track)
View More
Reimagining Dry Eye Disease: Delineating the Role of Evaporation From Inflammation and Insights Into Optimizing Treatment (CME Track)
View More
19th Annual Controversies in Modern Eye Care
May 4, 2025
Register Now!
(CME Track) Community Practice Connections™: Advancing the Optimal Diagnosis & Treatment of Thyroid Eye Disease
View More
(COPE Track) Community Practice Connections™: Advancing the Optimal Diagnosis & Treatment of Thyroid Eye Disease
View More
Outlining the New Standard in Geographic Atrophy: Optimizing Care Within the Modern Treatment Paradigm (CME Track)
View More
Outlining the New Standard in Geographic Atrophy: Optimizing Care Within the Modern Treatment Paradigm (COPE Track)
View More
Collaborative Care Symposium
May 30-31, 2025
Register Now!
Community Practice Connections™: Novel Therapies for Neovascular Retinal Disease – Expert Analysis of New Key Data
View More
Latest Advances in X-Linked Retinitis Pigmentosa: Optimizing Diagnosis and Developments in Gene Therapy
View More
Community Practice Connections™: Innovations and Interdisciplinary Approaches in Glaucoma Management—Expanding the Treatment Arsenal (CME Track)
View More
Community Practice Connections™: Innovations and Interdisciplinary Approaches in Glaucoma Management—Expanding the Treatment Arsenal (COPE Track)
View More
Road Mapping the Treat-and-Extend Protocol in nAMD and DME – When Time Is Sight (CME Track)
View More
Improving dry eye comfort and vision with lipid-containing lubricating drops
November 5th 2024The lipid-containing lubricating drop established noninferiority in comfort when compared to non-lipid drops, and the lipid-containing group also exhibited statistically significant improvements in visual quality at both day 7 and day 30, highlighting the potential benefits of this formulation for patients.
Aldeyra Therapeutics resubmits NDA for reproxalap for DED signs and symptoms treatment
October 3rd 2024Reproxalap was previously found to be statistically superior to vehicle for the primary endpoint of ocular discomfort (P=0.004) in a Phase 3 randomized, double-masked, vehicle-controlled dry eye chamber clinical trial.
Bausch + Lomb shares findings from State of Dry Eye survey
July 8th 2024The survey found that most participants may not know that their symptoms could be associated with eye dryness, including redness, fluctuating vision, a scratch, gritty, tired, or heavy feeling in the eye, or overall eye irritation.